Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study

被引:4
|
作者
Ullah, Asad [1 ]
Saeed, Omer [2 ]
Karki, Nabin Raj [3 ]
Goodbee, Mya [4 ]
Yasinzai, Abdul Qahar Khan [5 ]
Waheed, Abdul [6 ]
Heneidi, Saleh [7 ]
Thomas, Anish [8 ]
Karim, Nagla Abdel [9 ]
Johnson, Joyce [1 ]
Del Rivero, Jaydira [8 ]
Khan, Jaffar [2 ]
机构
[1] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA
[2] Indiana Univ, Indiana Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Univ S Alabama, Dept Hematol & Oncol, Mobile, AL 36688 USA
[4] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA
[5] Bolan Med Coll, Dept Med, Quetta 83700, Pakistan
[6] San Joaquin Gen Hosp, Dept Surg, San Joaquin, CA 95231 USA
[7] Cedars Sinai Med Ctr, Dept Mol Pathol, Los Angeles, CA 90048 USA
[8] Natl Inst Hlth NIH, Dept Hematol & Oncol, Bethesda, MD 20814 USA
[9] Inova Schar Canc Inst, Dept Hematol & Oncol, Fairfax, VA 22031 USA
关键词
combined small cell; lung cancer; histology; chemotherapy; molecular changes; CANCER; SCLC;
D O I
10.3390/jcm12030991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Primary lung cancer is the most common cause of cancer-related mortality in the United States (US). Approximately 90% of lung cancers are associated with smoking and the use of other tobacco products. Based on histology, lung cancers are divided into small-cell lung carcinomas (SCLCs) and non-small-cell lung carcinomas (NSCLCs). Most SCLCs are of the pure subtype, while the rare combined SCLCs contain elements of both small-cell and non-small-cell morphologies. This study sought to evaluate the demographics, clinical factors, molecular abnormalities, treatment approaches, and survival outcomes with combined SCLC and NSCLCs. Materials and Methods: Data on 2126 combined SCLC patients was extracted from the Surveillance Epidemiology and End Result (SEER) database from 2000 to 2018. Data extracted for analyses included age, sex, race, tumor size, tumor location, metastasis status, stage at diagnosis, treatment received, and treatment outcomes. Multivariate analysis was performed using Statistical Product and Service Solutions (SPSS) software. Results: The patients had a median age of 68 years; 43.9% of the patients were female and 56.1% were male; 84.5% were White and 11.7% were African Americans. The majority of patients had a poorly differentiated disease at 29.6%; 17% were undifferentiated, 3.2% were moderately differentiated, and 0.8% were well differentiated. Chemotherapy was the most common treatment modality (45.3%); 17% underwent surgery only, 10.3% underwent surgery followed by adjuvant chemotherapy, and 10% underwent radiation after surgery. Five-year cancer-specific survival was 15.2% with surgery alone, and combined surgery and chemotherapy provided the highest percentages (38.3% and 34.7%, respectively). Females had significantly higher 1- and 5-year cancer-specific survival rates compared to males (59.3% and 29.9% vs. 48.0% and 23.7, respectively; p < 0.001). Well-differentiated tumors had significantly higher survival compared to other gradings (p < 0.001). Survival decreased as tumor staging moved distally from localized to regional to distant (p < 0.001). Metastasis to bone, liver, brain, and lung significantly decreased survival in comparison to patients who did not have any metastasis (p < 0.001). Females had significantly shorter survival compared to their counterparts when metastasis was to the bone, brain, or liver (p < 0.001). Multivariate analysis identified male sex (Hazard Ratio (HR) = 1.2), undifferentiated grade (HR = 1.9), regional extent of disease (HR = 1.7), distant extent of disease (HR = 3.7), and metastasis to liver (HR = 3.5) as variables associated with worse survival. Conclusion: Combined SCLC is overall very rare. However, the frequency of presentation with combined SCLC is on the rise, in part due to improvements in diagnostic techniques. Despite advances in therapies, treating combined SCLC is challenging, and novel therapies are not utilized, owing to low rates of targetable mutations. Combined SCLC has higher survival rates if well differentiated.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
    M. Dómine Gómez
    T. Morán Bueno
    A. Artal Cortés
    J. Remon Masip
    P. Lianes Barragán
    Clinical and Translational Oncology, 2013, 15 : 985 - 990
  • [42] SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
    Domine Gomez, M.
    Moran Bueno, T.
    Artal Cortes, A.
    Remon Masip, J.
    Lianes Barragan, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (12) : 985 - 990
  • [43] Navigating treatment combinations in small-cell lung cancer
    Li, Ning
    Wang, Si-Yu
    NATURE MEDICINE, 2024, : 2731 - 2732
  • [44] Advances in antiangiogenic treatment of small-cell lung cancer
    Lu, Hongyang
    Jiang, Zhiming
    ONCOTARGETS AND THERAPY, 2017, 10 : 353 - 359
  • [45] Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study
    Cattrini, Carlo
    Cerbone, Luigi
    Rubagotti, Alessandra
    Zinoli, Linda
    Latocca, Maria Maddalena
    Messina, Carlo
    Zanardi, Elisa
    Boccardo, Francesco
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : E724 - E732
  • [46] Role of adjuvant therapy in early-stage small-cell lung cancer: comment on a population-based cohort study of patients with early-stage small-cell lung cancer
    Saji, Hisashi
    Marushima, Hideki
    Nakamura, Haruhiko
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1404 - E1407
  • [47] Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study
    Blackhall, Fiona
    Girard, Nicolas
    Livartowski, Alain
    McDonald, Laura
    Roset, Montserrat
    Lara, Nuria
    Garcia, Ariadna Juarez
    BMJ OPEN, 2023, 13 (02):
  • [48] Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese Oncologists
    Xu, Chang
    Li, Meng
    Cai, Xuwei
    Yuan, Shuanghu
    Cao, Jianzhong
    Zhu, Shuchai
    Chen, Ming
    Bi, Nan
    Hu, Xiao
    Li, Jiancheng
    Zhou, Wei
    Wang, Ping
    Zhao, Lujun
    Liu, Ningbo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Treatment patterns in stage III non-small-cell lung cancer patients: a population-based study using German cancer registry data
    Bedir, Ahmed
    Mehrotra, Sneha
    Gnuechtel, Jessica
    Vordermark, Dirk
    Medenwald, Daniel
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 15489 - 15497
  • [50] Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients A Real-world Evidence Study
    Yusuf, Dimas
    Walton, Ryan N.
    Hurry, Manjusha
    Farrer, Christie
    Bebb, D. Gwyn
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (09): : 615 - 620